[{"id":"fd4f177e-f85d-440b-907a-20a6e87e3329","acronym":"PRO-ACTIVE","url":"https://clinicaltrials.gov/study/NCT07469709","created_at":"2026-03-28T01:44:12.315Z","updated_at":"2026-03-28T01:44:12.315Z","phase":"","brief_title":"A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks","source_id_and_acronym":"NCT07469709 - PRO-ACTIVE","lead_sponsor":"Fondazione del Piemonte per l'Oncologia","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"],"overall_status":"Recruiting","enrollment":" Enrollment 850","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2026-03-13"},{"id":"66ccecbb-fe4e-496e-997f-7e4c2aa7798b","acronym":"","url":"https://clinicaltrials.gov/study/NCT07080242","created_at":"2025-07-26T13:29:22.344Z","updated_at":"2025-07-26T13:29:22.344Z","phase":"Phase 1","brief_title":"Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors","source_id_and_acronym":"NCT07080242","lead_sponsor":"SystImmune Inc.","biomarkers":" DLL3","pipe":"","alterations":" ","tags":["DLL3"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-07-23"},{"id":"44c07294-8489-4b3a-b2ed-b2c7e11ad982","acronym":"NCI#10057","url":"https://clinicaltrials.gov/study/NCT02978625","created_at":"2021-01-18T14:39:10.615Z","updated_at":"2025-02-25T13:48:20.165Z","phase":"Phase 2","brief_title":"Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers","source_id_and_acronym":"NCT02978625 - NCI#10057","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • ALK • NECTIN1","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["PD-L1 • ALK • NECTIN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Imlygic (talimogene laherparepvec) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 09/27/2017","start_date":" 09/27/2017","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-21"},{"id":"9c255554-467f-443d-b9bf-0883f980d302","acronym":"SGNB6A-001","url":"https://clinicaltrials.gov/study/NCT04389632","created_at":"2021-08-12T17:53:41.583Z","updated_at":"2025-02-25T13:53:17.348Z","phase":"Phase 1","brief_title":"A Study of SGN-B6A in Advanced Solid Tumors","source_id_and_acronym":"NCT04389632 - SGNB6A-001","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • sigvotatug vedotin (PF-08046047)"],"overall_status":"Recruiting","enrollment":" Enrollment 824","initiation":"Initiation: 06/08/2020","start_date":" 06/08/2020","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 02/28/2028","study_completion_date":" 02/28/2028","last_update_posted":"2025-02-20"},{"id":"5b6f5e90-5c5a-4cbe-a9af-ed1c1a32c726","acronym":"","url":"https://clinicaltrials.gov/study/NCT04975152","created_at":"2021-07-23T13:52:34.008Z","updated_at":"2025-02-25T14:02:26.800Z","phase":"Phase 1","brief_title":"Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma","source_id_and_acronym":"NCT04975152","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/22/2021","start_date":" 10/22/2021","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-19"},{"id":"f8d87fba-1ad4-4662-baab-e93772837874","acronym":"Agni-01","url":"https://clinicaltrials.gov/study/NCT06060613","created_at":"2023-09-29T19:11:12.291Z","updated_at":"2025-02-25T14:03:51.690Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of OBX-115 in Advanced Solid Tumors","source_id_and_acronym":"NCT06060613 - Agni-01","lead_sponsor":"Obsidian Therapeutics, Inc.","biomarkers":" PD-L1 • BRAF • PD-1","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["PD-L1 • BRAF • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • OBX-115"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 10/25/2023","start_date":" 10/25/2023","primary_txt":" Primary completion: 10/30/2025","primary_completion_date":" 10/30/2025","study_txt":" Completion: 10/30/2027","study_completion_date":" 10/30/2027","last_update_posted":"2025-02-19"},{"id":"f9665a10-dce3-43c7-a423-8c44b5bd6d32","acronym":"","url":"https://clinicaltrials.gov/study/NCT03944941","created_at":"2021-01-18T19:25:25.225Z","updated_at":"2025-02-25T14:15:21.839Z","phase":"Phase 2","brief_title":"Avelumab with or Without Cetuximab in Treating Patients with Advanced Skin Squamous Cell Cancer","source_id_and_acronym":"NCT03944941","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PD-L1 • CD4","pipe":"","alterations":" ","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Bavencio (avelumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/17/2019","start_date":" 06/17/2019","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-02-18"},{"id":"eda22fa5-a154-4718-aaaf-d2fb8460e402","acronym":"","url":"https://clinicaltrials.gov/study/NCT02721459","created_at":"2021-01-18T13:18:50.231Z","updated_at":"2025-02-25T16:30:48.412Z","phase":"Phase 1","brief_title":"XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma","source_id_and_acronym":"NCT02721459","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Cotellic (cobimetinib) • XL888"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 09/07/2016","start_date":" 09/07/2016","primary_txt":" Primary completion: 10/31/2019","primary_completion_date":" 10/31/2019","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2025-02-07"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"dade1c51-e09a-44d8-a094-79a994b13e05","acronym":"Alliance A091605","url":"https://clinicaltrials.gov/study/NCT03304639","created_at":"2021-01-19T14:56:18.448Z","updated_at":"2025-02-25T16:36:59.101Z","phase":"Phase 2","brief_title":"Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma","source_id_and_acronym":"NCT03304639 - Alliance A091605","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 06/12/2018","start_date":" 06/12/2018","primary_txt":" Primary completion: 06/07/2022","primary_completion_date":" 06/07/2022","study_txt":" Completion: 09/22/2025","study_completion_date":" 09/22/2025","last_update_posted":"2025-02-06"},{"id":"42d2a0f4-bf25-41be-9b41-ecad4c959f5d","acronym":"CK-301-101","url":"https://clinicaltrials.gov/study/NCT03212404","created_at":"2021-01-18T15:50:41.447Z","updated_at":"2025-02-25T16:59:32.024Z","phase":"Phase 1","brief_title":"Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers","source_id_and_acronym":"NCT03212404 - CK-301-101","lead_sponsor":"Checkpoint Therapeutics, Inc.","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Unloxcyt (cosibelimab-ipdl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 272","initiation":"Initiation: 09/20/2017","start_date":" 09/20/2017","primary_txt":" Primary completion: 11/18/2021","primary_completion_date":" 11/18/2021","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-03"},{"id":"412de90b-4e3b-4146-9e47-4f34d9a4603a","acronym":"QUILT-3.055","url":"https://clinicaltrials.gov/study/NCT03228667","created_at":"2021-01-18T15:56:08.764Z","updated_at":"2025-02-25T17:35:53.589Z","phase":"Phase 2","brief_title":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","source_id_and_acronym":"NCT03228667 - QUILT-3.055","lead_sponsor":"ImmunityBio, Inc.","biomarkers":" BRAF • ALK • MSI","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • MSI-H/dMMR • PD-L1 overexpression • BRAF V600 • BRAF wild-type","tags":["BRAF • ALK • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • MSI-H/dMMR • PD-L1 overexpression • BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • docetaxel • Bavencio (avelumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/11/2018","start_date":" 12/11/2018","primary_txt":" Primary completion: 08/31/2029","primary_completion_date":" 08/31/2029","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-01-29"},{"id":"d78d7b46-d2cc-485a-8c04-81f9d73189d4","acronym":"KEYNOTE-E28","url":"https://clinicaltrials.gov/study/NCT04429542","created_at":"2021-01-18T21:20:02.191Z","updated_at":"2025-02-25T16:10:23.024Z","phase":"Phase 1","brief_title":"Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors","source_id_and_acronym":"NCT04429542 - KEYNOTE-E28","lead_sponsor":"Bicara Therapeutics","biomarkers":" PD-L1","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • KRAS G12D • EGFR amplification • PD-L1 negative • RAS wild-type • KRAS G12 • KRAS G13 • EGFR negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • KRAS G12D • EGFR amplification • PD-L1 negative • RAS wild-type • KRAS G12 • KRAS G13 • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ficerafusp alfa (BCA101)"],"overall_status":"Recruiting","enrollment":" Enrollment 292","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-01-27"},{"id":"d2fe552c-f100-425e-934e-b8a426721a46","acronym":"IGNYTE","url":"https://clinicaltrials.gov/study/NCT03767348","created_at":"2021-01-18T18:38:28.476Z","updated_at":"2025-02-25T14:27:51.295Z","phase":"Phase 2","brief_title":"Study of RP1 Monotherapy and RP1 in Combination With Nivolumab","source_id_and_acronym":"NCT03767348 - IGNYTE","lead_sponsor":"Replimune Inc.","biomarkers":" BRAF • MSI","pipe":" | ","alterations":" MSI-H/dMMR • BRAF mutation","tags":["BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Tudriqev (vusolimogene oderparepvec-wtpg)"],"overall_status":"Recruiting","enrollment":" Enrollment 340","initiation":"Initiation: 09/20/2017","start_date":" 09/20/2017","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-01-24"},{"id":"80d5522f-7e62-4840-9814-99046b8adfc5","acronym":"DEKA-1","url":"https://clinicaltrials.gov/study/NCT05704985","created_at":"2023-01-30T15:59:33.980Z","updated_at":"2025-02-25T17:31:52.518Z","phase":"Phase 1","brief_title":"Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors","source_id_and_acronym":"NCT05704985 - DEKA-1","lead_sponsor":"DEKA Biosciences","biomarkers":" EGFR • IL2 • IL10","pipe":" | ","alterations":" EGFR expression","tags":["EGFR • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • carboplatin • paclitaxel • 5-fluorouracil • capecitabine • oxaliplatin • DK210 (EGFR)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/03/2023","start_date":" 04/03/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-01-23"},{"id":"19899ca6-56d4-4952-beaa-c4745d820e14","acronym":"","url":"https://clinicaltrials.gov/study/NCT03131908","created_at":"2021-01-18T15:25:52.146Z","updated_at":"2025-02-25T13:12:18.989Z","phase":"Phase 1/2","brief_title":"Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss","source_id_and_acronym":"NCT03131908","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN loss","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN loss"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • GSK2636771"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 07/17/2017","start_date":" 07/17/2017","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-01-13"},{"id":"6fb8362c-e7e1-47e4-848c-a1f5eb984935","acronym":"KEYNOTE-G08","url":"https://clinicaltrials.gov/study/NCT05824975","created_at":"2024-01-29T17:20:35.977Z","updated_at":"2025-02-25T16:18:44.543Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","source_id_and_acronym":"NCT05824975 - KEYNOTE-G08","lead_sponsor":"GI Innovation, Inc.","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • doxorubicin hydrochloride • Halaven (eribulin mesylate)"],"overall_status":"Recruiting","enrollment":" Enrollment 358","initiation":"Initiation: 05/30/2023","start_date":" 05/30/2023","primary_txt":" Primary completion: 11/12/2025","primary_completion_date":" 11/12/2025","study_txt":" Completion: 04/24/2027","study_completion_date":" 04/24/2027","last_update_posted":"2024-11-25"},{"id":"6bba22c3-f62e-47e0-bd6a-d981df9489ab","acronym":"Precis-mel 2","url":"https://clinicaltrials.gov/study/NCT06605443","created_at":"2025-02-26T14:54:27.285Z","updated_at":"2025-02-26T14:54:27.285Z","phase":"","brief_title":"Precision Medicine for L/GCMN and Melanoma 2","source_id_and_acronym":"NCT06605443 - Precis-mel 2","lead_sponsor":"Fundacion Clinic per a la Recerca Biomédica","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/01/2024","start_date":" 11/01/2024","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-09-20"},{"id":"a9b98e89-64a8-4245-99e7-c014eaeac52a","acronym":"KEYNOTE-B59","url":"https://clinicaltrials.gov/study/NCT04977453","created_at":"2024-02-20T21:30:41.481Z","updated_at":"2025-02-25T16:16:30.492Z","phase":"Phase 1/2","brief_title":"GI-101 As a Single Agent or in Combination with Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors","source_id_and_acronym":"NCT04977453 - KEYNOTE-B59","lead_sponsor":"GI Innovation, Inc.","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib) • efdelikofusp alfa (GI-101)"],"overall_status":"Recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 08/02/2021","start_date":" 08/02/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-09-19"},{"id":"d3894fe7-c2a5-46ce-9212-204653c06726","acronym":"","url":"https://clinicaltrials.gov/study/NCT00033137","created_at":"2021-01-18T00:01:03.867Z","updated_at":"2024-07-02T16:34:26.356Z","phase":"","brief_title":"Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer","source_id_and_acronym":"NCT00033137","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLCN","pipe":"","alterations":" ","tags":["FLCN"],"overall_status":"Recruiting","enrollment":" Enrollment 950","initiation":"Initiation: 05/13/2002","start_date":" 05/13/2002","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-06-13"},{"id":"607c59af-1fd9-4afc-8491-e33c116441ac","acronym":"PNeoVCA","url":"https://clinicaltrials.gov/study/NCT05269381","created_at":"2022-03-08T17:52:43.258Z","updated_at":"2024-07-02T16:34:26.810Z","phase":"Phase 1/2","brief_title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT05269381 - PNeoVCA","lead_sponsor":"Mayo Clinic","biomarkers":" KRAS • BRAF • ALK • TMB • MSI • ROS1 • NTRK","pipe":" | ","alterations":" TMB-H","tags":["KRAS • BRAF • ALK • TMB • MSI • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • Leukine (sargramostim) • neoantigen peptide vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/31/2022","start_date":" 03/31/2022","primary_txt":" Primary completion: 02/24/2025","primary_completion_date":" 02/24/2025","study_txt":" Completion: 02/24/2026","study_completion_date":" 02/24/2026","last_update_posted":"2024-06-12"},{"id":"c8222add-71ac-46cf-97f8-54e3d1c741e3","acronym":"INTASYL PH-762","url":"https://clinicaltrials.gov/study/NCT06014086","created_at":"2023-08-28T14:08:35.359Z","updated_at":"2024-07-02T16:34:27.237Z","phase":"Phase 1","brief_title":"Intratumoral PH-762 for Cutaneous Carcinoma","source_id_and_acronym":"NCT06014086 - INTASYL PH-762","lead_sponsor":"Phio Pharmaceuticals Inc.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/07/2023","start_date":" 11/07/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-06-11"},{"id":"4574703b-19bd-4bd3-9dd9-9adace3f6487","acronym":"","url":"https://clinicaltrials.gov/study/NCT05896839","created_at":"2023-06-09T16:06:51.642Z","updated_at":"2024-07-02T16:34:27.634Z","phase":"Phase 1/2","brief_title":"Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer","source_id_and_acronym":"NCT05896839","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • sirolimus • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 08/11/2024","start_date":" 08/11/2024","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-06-10"},{"id":"9de9a1df-22ec-481b-a91e-eefe5c853bd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02791334","created_at":"2021-01-18T13:42:09.109Z","updated_at":"2024-07-02T16:34:59.807Z","phase":"Phase 1","brief_title":"A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors","source_id_and_acronym":"NCT02791334","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • ER • PGR • MSI","pipe":" | ","alterations":" MSI-H/dMMR • HER-2 overexpression • HER-2 negative","tags":["HER-2 • ER • PGR • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • HER-2 overexpression • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Cyramza (ramucirumab) • merestinib (LY2801653) • lodapolimab (LY3300054) • LY3321367"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 215","initiation":"Initiation: 06/29/2016","start_date":" 06/29/2016","primary_txt":" Primary completion: 05/22/2020","primary_completion_date":" 05/22/2020","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-05-31"}]